Neurizon Therapeutics (FRA:ECQ0) Debt-to-Equity : 0.00 (As of Dec. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Neurizon Therapeutics Debt-to-Equity?

Neurizon Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €0.00 Mil. Neurizon Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €0.00 Mil. Neurizon Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2024 was €7.20 Mil. Neurizon Therapeutics's debt to equity for the quarter that ended in Dec. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Neurizon Therapeutics's Debt-to-Equity or its related term are showing as below:

During the past 6 years, the highest Debt-to-Equity Ratio of Neurizon Therapeutics was 0.17. The lowest was 0.05. And the median was 0.12.

FRA:ECQ0's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

Neurizon Therapeutics Debt-to-Equity Historical Data

The historical data trend for Neurizon Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurizon Therapeutics Debt-to-Equity Chart

Neurizon Therapeutics Annual Data

Trend

Jun01

Jun02

Jun03

Jun04

Jun05

Jun24

Debt-to-Equity

Get a 7-Day Free Trial

0.34

0.24

0.06

0.08

Neurizon Therapeutics Semi-Annual Data
	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Dec13	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23	Jun24	Dec24
Debt-to-Equity	Get a 7-Day Free Trial															0.15	0.14	-	-	-

Competitive Comparison of Neurizon Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Neurizon Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neurizon Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neurizon Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Neurizon Therapeutics's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Neurizon Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Neurizon Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Jun. 2005 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.146	+	0.036)	/	2.441
	=	0.07

Neurizon Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	7.202
	=	0.00

Neurizon Therapeutics (FRA:ECQ0) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Neurizon Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Neurizon Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Neurizon Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neurizon Therapeutics Ltd (FRA:ECQ0) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

NUZ:Australia

Address

96-100 Albert Road, Level 4, South Melbourne, Melbourne, VIC, AUS, 3205

Website

https://www.neurizon.com

Neurizon Therapeutics Ltd is a clinical-stage biotech company that develops drug discovery intellectual property for the treatment of different types of neurodegenerative diseases. Its product pipeline is NUZ-001 (S-Monepantel).

Neurizon Therapeutics Headlines

No Headlines